Understanding Risk Communication Through Patient Narratives About Complex Antithrombotic Therapies

The purpose of this study was to explore how patients use narratives to create coherent understandings of risks associated with complex antithrombotic therapies. We led four focus groups consisting of patients older than 65 years of age who had a diagnosis of cardiovascular disease and were using a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Qualitative health research 2010-08, Vol.20 (8), p.1155-1165
Hauptverfasser: Andreas, Dorothy C., Abraham, Neena S., Naik, Aanand D., Street, Richard L., Sharf, Barbara F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1165
container_issue 8
container_start_page 1155
container_title Qualitative health research
container_volume 20
creator Andreas, Dorothy C.
Abraham, Neena S.
Naik, Aanand D.
Street, Richard L.
Sharf, Barbara F.
description The purpose of this study was to explore how patients use narratives to create coherent understandings of risks associated with complex antithrombotic therapies. We led four focus groups consisting of patients older than 65 years of age who had a diagnosis of cardiovascular disease and were using a prescription for cardioprotective agents, such as aspirin, anticoagulants, and/or antiplatelets. The participants’ stories were retrospective accounts about physician and patient interactions and adverse events organized in the plot structure of a trial-and-error story. The trial-and-error narrative structure emphasizes patients’ idiosyncrasies and reasons why they expect to experience adverse events from changes in treatment. Any fears that they might have had about these risks were mitigated by physician expertise, patient responsibility, and medical technology. Patients who expressed concern about not having sufficient access to medical expertise (e.g., physicians, laboratory tests) seemed less willing to accept risks. The trial-and-error risk narratives helped patients deal with ambiguity and uncertainty about the outcomes of their therapies, and revealed patients’ orientations to the risks they faced.
doi_str_mv 10.1177/1049732310370154
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754135023</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1049732310370154</sage_id><sourcerecordid>733996966</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-c81062a21ad9ea6f7690b7666bfc9daf16124932f75074df38d3584bc892fb703</originalsourceid><addsrcrecordid>eNqFkUtLxDAUhYMozvjYu5LixlU17zTLYfAFg4rouqRtOmZskzFJRf-9GcYHDIir3HC_c-69HACOEDxDSIhzBKkUBBMEiYCI0S0wRozhXDAmtlOd2vmqPwJ7ISwghAISsgtGGFKKCWVjUD3ZRvsQlW2MnWcPJrxkU9f3gzW1isbZ7PHZu2H-nN2nr7Yxu1Xep_JNh2xSuSGu8GWn37OJjSYmuK9cNHXSaa-WRocDsNOqLujDr3cfPF1ePE6v89nd1c10MstrIlnM6wJBjhVGqpFa8VZwCSvBOa_aWjaqRRxhKgluBYOCNi0pGsIKWtWFxG2VDtsHp2vfpXevgw6x7E2oddcpq90QSsEoIgxi8j9JiJRccp7Ikw1y4QZv0xmloJQWLC2VILiGau9C8Lotl970yn-UCJarnMrNnJLk-Mt3qHrd_Ai-g0lAvgaCmuvfoX8afgL9sZnd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>744485612</pqid></control><display><type>article</type><title>Understanding Risk Communication Through Patient Narratives About Complex Antithrombotic Therapies</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Andreas, Dorothy C. ; Abraham, Neena S. ; Naik, Aanand D. ; Street, Richard L. ; Sharf, Barbara F.</creator><creatorcontrib>Andreas, Dorothy C. ; Abraham, Neena S. ; Naik, Aanand D. ; Street, Richard L. ; Sharf, Barbara F.</creatorcontrib><description>The purpose of this study was to explore how patients use narratives to create coherent understandings of risks associated with complex antithrombotic therapies. We led four focus groups consisting of patients older than 65 years of age who had a diagnosis of cardiovascular disease and were using a prescription for cardioprotective agents, such as aspirin, anticoagulants, and/or antiplatelets. The participants’ stories were retrospective accounts about physician and patient interactions and adverse events organized in the plot structure of a trial-and-error story. The trial-and-error narrative structure emphasizes patients’ idiosyncrasies and reasons why they expect to experience adverse events from changes in treatment. Any fears that they might have had about these risks were mitigated by physician expertise, patient responsibility, and medical technology. Patients who expressed concern about not having sufficient access to medical expertise (e.g., physicians, laboratory tests) seemed less willing to accept risks. The trial-and-error risk narratives helped patients deal with ambiguity and uncertainty about the outcomes of their therapies, and revealed patients’ orientations to the risks they faced.</description><identifier>ISSN: 1049-7323</identifier><identifier>EISSN: 1552-7557</identifier><identifier>DOI: 10.1177/1049732310370154</identifier><identifier>PMID: 20442345</identifier><identifier>CODEN: QHREEM</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Aged ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Cardiovascular disease ; Cardiovascular Diseases - drug therapy ; Communication ; Critical incidents ; Doctors ; Drug therapy ; Expertise ; Female ; Fibrinolytic Agents - therapeutic use ; Focus Groups ; Health technology assessment ; Humans ; Laboratories ; Male ; Narration ; Narratives ; Older people ; Patients ; Physician patient relationships ; Platelet Aggregation Inhibitors - therapeutic use ; Prescriptions ; Retrospective Studies ; Risk ; Risk Factors ; Surveys and Questionnaires ; Thromboembolism - drug therapy</subject><ispartof>Qualitative health research, 2010-08, Vol.20 (8), p.1155-1165</ispartof><rights>The Author(s) 2010</rights><rights>Copyright SAGE PUBLICATIONS, INC. Aug 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-c81062a21ad9ea6f7690b7666bfc9daf16124932f75074df38d3584bc892fb703</citedby><cites>FETCH-LOGICAL-c395t-c81062a21ad9ea6f7690b7666bfc9daf16124932f75074df38d3584bc892fb703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1049732310370154$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1049732310370154$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,30976,30977,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20442345$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andreas, Dorothy C.</creatorcontrib><creatorcontrib>Abraham, Neena S.</creatorcontrib><creatorcontrib>Naik, Aanand D.</creatorcontrib><creatorcontrib>Street, Richard L.</creatorcontrib><creatorcontrib>Sharf, Barbara F.</creatorcontrib><title>Understanding Risk Communication Through Patient Narratives About Complex Antithrombotic Therapies</title><title>Qualitative health research</title><addtitle>Qual Health Res</addtitle><description>The purpose of this study was to explore how patients use narratives to create coherent understandings of risks associated with complex antithrombotic therapies. We led four focus groups consisting of patients older than 65 years of age who had a diagnosis of cardiovascular disease and were using a prescription for cardioprotective agents, such as aspirin, anticoagulants, and/or antiplatelets. The participants’ stories were retrospective accounts about physician and patient interactions and adverse events organized in the plot structure of a trial-and-error story. The trial-and-error narrative structure emphasizes patients’ idiosyncrasies and reasons why they expect to experience adverse events from changes in treatment. Any fears that they might have had about these risks were mitigated by physician expertise, patient responsibility, and medical technology. Patients who expressed concern about not having sufficient access to medical expertise (e.g., physicians, laboratory tests) seemed less willing to accept risks. The trial-and-error risk narratives helped patients deal with ambiguity and uncertainty about the outcomes of their therapies, and revealed patients’ orientations to the risks they faced.</description><subject>Aged</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Communication</subject><subject>Critical incidents</subject><subject>Doctors</subject><subject>Drug therapy</subject><subject>Expertise</subject><subject>Female</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Focus Groups</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Male</subject><subject>Narration</subject><subject>Narratives</subject><subject>Older people</subject><subject>Patients</subject><subject>Physician patient relationships</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Prescriptions</subject><subject>Retrospective Studies</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>Surveys and Questionnaires</subject><subject>Thromboembolism - drug therapy</subject><issn>1049-7323</issn><issn>1552-7557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFkUtLxDAUhYMozvjYu5LixlU17zTLYfAFg4rouqRtOmZskzFJRf-9GcYHDIir3HC_c-69HACOEDxDSIhzBKkUBBMEiYCI0S0wRozhXDAmtlOd2vmqPwJ7ISwghAISsgtGGFKKCWVjUD3ZRvsQlW2MnWcPJrxkU9f3gzW1isbZ7PHZu2H-nN2nr7Yxu1Xep_JNh2xSuSGu8GWn37OJjSYmuK9cNHXSaa-WRocDsNOqLujDr3cfPF1ePE6v89nd1c10MstrIlnM6wJBjhVGqpFa8VZwCSvBOa_aWjaqRRxhKgluBYOCNi0pGsIKWtWFxG2VDtsHp2vfpXevgw6x7E2oddcpq90QSsEoIgxi8j9JiJRccp7Ikw1y4QZv0xmloJQWLC2VILiGau9C8Lotl970yn-UCJarnMrNnJLk-Mt3qHrd_Ai-g0lAvgaCmuvfoX8afgL9sZnd</recordid><startdate>201008</startdate><enddate>201008</enddate><creator>Andreas, Dorothy C.</creator><creator>Abraham, Neena S.</creator><creator>Naik, Aanand D.</creator><creator>Street, Richard L.</creator><creator>Sharf, Barbara F.</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201008</creationdate><title>Understanding Risk Communication Through Patient Narratives About Complex Antithrombotic Therapies</title><author>Andreas, Dorothy C. ; Abraham, Neena S. ; Naik, Aanand D. ; Street, Richard L. ; Sharf, Barbara F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-c81062a21ad9ea6f7690b7666bfc9daf16124932f75074df38d3584bc892fb703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Communication</topic><topic>Critical incidents</topic><topic>Doctors</topic><topic>Drug therapy</topic><topic>Expertise</topic><topic>Female</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Focus Groups</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Male</topic><topic>Narration</topic><topic>Narratives</topic><topic>Older people</topic><topic>Patients</topic><topic>Physician patient relationships</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Prescriptions</topic><topic>Retrospective Studies</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>Surveys and Questionnaires</topic><topic>Thromboembolism - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andreas, Dorothy C.</creatorcontrib><creatorcontrib>Abraham, Neena S.</creatorcontrib><creatorcontrib>Naik, Aanand D.</creatorcontrib><creatorcontrib>Street, Richard L.</creatorcontrib><creatorcontrib>Sharf, Barbara F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Qualitative health research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andreas, Dorothy C.</au><au>Abraham, Neena S.</au><au>Naik, Aanand D.</au><au>Street, Richard L.</au><au>Sharf, Barbara F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Understanding Risk Communication Through Patient Narratives About Complex Antithrombotic Therapies</atitle><jtitle>Qualitative health research</jtitle><addtitle>Qual Health Res</addtitle><date>2010-08</date><risdate>2010</risdate><volume>20</volume><issue>8</issue><spage>1155</spage><epage>1165</epage><pages>1155-1165</pages><issn>1049-7323</issn><eissn>1552-7557</eissn><coden>QHREEM</coden><abstract>The purpose of this study was to explore how patients use narratives to create coherent understandings of risks associated with complex antithrombotic therapies. We led four focus groups consisting of patients older than 65 years of age who had a diagnosis of cardiovascular disease and were using a prescription for cardioprotective agents, such as aspirin, anticoagulants, and/or antiplatelets. The participants’ stories were retrospective accounts about physician and patient interactions and adverse events organized in the plot structure of a trial-and-error story. The trial-and-error narrative structure emphasizes patients’ idiosyncrasies and reasons why they expect to experience adverse events from changes in treatment. Any fears that they might have had about these risks were mitigated by physician expertise, patient responsibility, and medical technology. Patients who expressed concern about not having sufficient access to medical expertise (e.g., physicians, laboratory tests) seemed less willing to accept risks. The trial-and-error risk narratives helped patients deal with ambiguity and uncertainty about the outcomes of their therapies, and revealed patients’ orientations to the risks they faced.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>20442345</pmid><doi>10.1177/1049732310370154</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1049-7323
ispartof Qualitative health research, 2010-08, Vol.20 (8), p.1155-1165
issn 1049-7323
1552-7557
language eng
recordid cdi_proquest_miscellaneous_754135023
source Applied Social Sciences Index & Abstracts (ASSIA); SAGE Complete A-Z List; MEDLINE
subjects Aged
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Cardiovascular disease
Cardiovascular Diseases - drug therapy
Communication
Critical incidents
Doctors
Drug therapy
Expertise
Female
Fibrinolytic Agents - therapeutic use
Focus Groups
Health technology assessment
Humans
Laboratories
Male
Narration
Narratives
Older people
Patients
Physician patient relationships
Platelet Aggregation Inhibitors - therapeutic use
Prescriptions
Retrospective Studies
Risk
Risk Factors
Surveys and Questionnaires
Thromboembolism - drug therapy
title Understanding Risk Communication Through Patient Narratives About Complex Antithrombotic Therapies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A29%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Understanding%20Risk%20Communication%20Through%20Patient%20Narratives%20About%20Complex%20Antithrombotic%20Therapies&rft.jtitle=Qualitative%20health%20research&rft.au=Andreas,%20Dorothy%20C.&rft.date=2010-08&rft.volume=20&rft.issue=8&rft.spage=1155&rft.epage=1165&rft.pages=1155-1165&rft.issn=1049-7323&rft.eissn=1552-7557&rft.coden=QHREEM&rft_id=info:doi/10.1177/1049732310370154&rft_dat=%3Cproquest_cross%3E733996966%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=744485612&rft_id=info:pmid/20442345&rft_sage_id=10.1177_1049732310370154&rfr_iscdi=true